Similarity-basedmachine learning methods for predicting drug-target interactions: A brief review

Briefings in Bioinformatics

Volumn 15, Issue 5, 2013, Pages 734-747

  Ding, Hao ^a   Takigawa, Ichigaku ^b   Mamitsuka, Hiroshi ^c,d   Zhu, Shanfeng ^a  

^a FUDAN UNIVERSITY   (China)

^b HOKKAIDO UNIVERSITY   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d School of Pharmaceutical Sciences of the same university   (Japan)

Author keywords

Drug discovery; Drug similarity; Drug target interaction prediction; Machine learning; Target similarity

Indexed keywords

ARTIFICIAL INTELLIGENCE; DRUG INTERACTION; THEORETICAL MODEL;

ARTIFICIAL INTELLIGENCE; DRUG INTERACTIONS; MODELS, THEORETICAL;

EID: 84928196309     PISSN: 14675463     EISSN: 14774054     Source Type: Journal    
DOI: 10.1093/bib/bbt056     Document Type: Article

References (68)

1. Hopkins AL. Drug discovery: predicting promiscuity. Nature 2009;462:167-8.
2. Lounkine E, Keiser MJ, Whitebread S, et al. Large-scale prediction and testing of drug activity on side-effect targets. Nature 2012;486:361-7.
3. Pauwels E, Stoven V, Yamanishi Y. Predicting drug sideeffect profiles: a chemical fragment-based approach. BMC Bioinformatics 2011;12:169.
4. Dudley JT, Deshpande T, Butte AJ. Exploiting drug-disease relationships for computational drug repositioning. Brief Bioinform 2011;12(4):303-11.
5. Swamidass SJ. Mining small-molecule screens to repurpose drugs. Brief Bioinform 2011;12(4):327-35.
6. Moriaud F, Richard SB, Adcock SA, et al. Identify drug repurposing candidates by mining the Protein Data Bank. Brief Bioinform 2011;12(4):336-40.
7. Hopkins AL, Groom CR. The druggable genome. NatRev Drug Discov 2002;1(9):727-30.
8. Dobson CM. Chemical space and biology. Nature 2004;432:824-8.
9. Kanehisa M, Goto S, Hattori M, et al. From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res 2006;34:D354-7.
10. Stockwell BR. Chemical genetics: ligand-based discovery of gene function. Nat RevGenet 2000;1(2):116-25.
11. Sayers EW, Barrett T, Benson DA, et al. Database resources of the National Center for Biotechnology Information. Nucleic Acids Res 2012;40:D13-25.
12. Whitebread S, Hamon J, Bojanic D, et al. Keynote review:in vitro safety pharmacology profiling: an essential tool for successful drug development. Drug DiscovToday 2005;10(21):1421-33.
13. Haggarty SJ, Koeller KM, Wong JC, et al. Multidimensional chemical genetic analysis of diversity-oriented synthesisderived deacetylase inhibitors using cell-based assays. Chem Biol 2003;10(5):383-96.
14. Kuruvilla FG, Shamji AF, Sternson SM, et al. Dissecting glucose signaling with diversity-oriented synthesis and small-molecule microarrays. Nature 2002;416:653-7.
15. Manly CJ, Louise-May S, Hammer JD. The impact of informatics and computational chemistry on synthesis and screening. Drug DiscovToday 2001;6(21):1101-10.
16. Shoichet BK, Bodian DL, Kuntz ID. Molecular docking using shape descriptors. J Comput Chem 1992; 13(3):380-97.
17. Rarey M, Kramer B, Lengauer T, et al. A fast flexible docking method using an incremental construction algorithm. JMol Biol 1996;261(3):470-89.
18. Halperin I, Ma B, Wolfson H, et al. Principles of docking:an overview of search algorithms and a guide to scoring functions. Proteins 2002;47(4):409-43.
19. Shoichet BK, McGovern SL, Wei B, et al. Lead discovery using molecular docking. Curr Opin Chem Biol 2002;6(4):439-46.
20. Cheng AC, Coleman RG, Smyth KT, et al. Structure-based maximal affinity model predicts small-molecule druggability. Nat Biotechnol 2007;25(1):71-5.
21. Ballesteros J, Palczewski K. G protein-coupled receptor drug discovery: implications from the crystal structure of rhodopsin. Curr OpinDrugDiscov Devel 2001;4(5):561-74.
22. Klabunde T, Hessler G. Drug design strategies for targeting G-protein-coupled receptors. Chembiochem 2002; 3(10):928-44.
23. Nagamine N, Sakakibara Y. Statistical prediction of protein chemical interactions based on chemical structure and mass spectrometry data. Bioinformatics 2007;23(15):2004-12.
24. Nagamine N, Shirakawa T, Minato Y, et al. Integrating statistical predictions and experimental verifications for enhancing protein-chemical interaction predictions in virtual screening. PLoSComput Biol 2009;5(6):e1000397.
25. Yabuuchi H, Niijima S, Takematsu H, et al. Analysis of multiple compound-protein interactions reveals novel bioactive molecules. Mol Syst Biol 2011;7:472.
26. Yamanishi Y, Araki M, Gutteridge A, et al. Prediction of drug-target interaction networks from the integration of chemical and genomic spaces. Bioinformatics 2008;24(13):i232-40.
27. Bleakley K, Yamanishi Y. Supervised prediction of drugtarget interactions using bipartite local models. Bioinformatics 2009;25(18):2397-403.
28. Jacob L, Vert JP. Protein-ligand interaction prediction: an improved chemogenomics approach. Bioinformatics 2008; 24(19):2149-56.
29. Xia Z, Wu LY, Zhou X, et al. Semi-supervised drug-protein interaction prediction from heterogeneous biological spaces. BMCSyst Biol 2010; 4(Suppl 2):S6.
30. Van Laarhoven T, Nabuurs SB, Marchiori E. Gaussian interaction profile kernels for predicting drug-target interaction. Bioinformatics 2011;27(21):3036-43.
31. Gonen M. Predicting drug-target interactions from chemical and genomic kernels using Bayesian matrix factorization. Bioinformatics 2012;28(18):2304-10.
32. Perlman L, Gottlieb A, Atias N, et al. Combining drug and gene similarity measures for drug-target elucidation. JComputBiol 2011;18(2):133-45.
33. Yamanishi Y, Kotera M, Kanehisa M, et al. Drug-target interaction prediction from chemical, genomic and pharmacological data in an integrated framework. Bioinformatics 2010;26(12):i246-54.
34. Zhu S, Okuno Y, Tsujimoto G, et al. A probabilistic model for mining implicit 'chemical compound-gene' relations from literature. Bioinformatics 2005; 21(Suppl 2):ii245-51.
35. Kuhn M, Campillos M, Gonzalez P, et al. Large-scale prediction of drug-target relationships. FEBS Lett 2008;582(8):1283-90.
36. Iskar M, Zeller G, Zhao XM, et al. Drug discovery in the age of systems biology: the rise of computational approaches for data integration. Curr Opin Biotechnol 2012; 23(4):609-16.
37. Koutsoukas A, Simms B, Kirchmair J, et al. From in silico target prediction to multi-target drug design: current databases, methods and applications. J Proteomics 2011; 74(12):2554-74.
38. Sanseau P, Koehler J. Editorial: computational methods for drug repurposing. Brief Bioinform 2011;12(4):301-2.
39. Schomburg I, Chang A, Ebeling C, et al. BRENDA, the enzyme database: updates and major new developments. Nucleic Acids Res 2004;32:D431-3.
40. Gunther S, Kuhn M, Dunkel M, et al. SuperTarget and matador: resources for exploring drug-target relationships. Nucleic Acids Res 2008;36:D919-22.
41. Wishart DS, Knox C, Guo AC, et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res 2008;36:D901-6.
42. Liu Y, Hu B, Fu C, et al. DCDB: drug combination database. Bioinformatics 2010;26(4):587-8.
43. Brooksbank C, Cameron G, Thornton J. The European Bioinformatics Institute's data resources. Nucleic Acids Res 2010;38:D17-25.
44. Kuhn M, Campillos M, Letunic I, et al. A side effect resource to capture phenotypic effects of drugs. Mol Syst Biol 2010;6:343.
45. Lamb J, Crawford ED, Peck D, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006;313:1929-35.
46. Breitkreutz BJ, Stark C, Reguly T, et al. The BioGRID interaction database: 2008 update. Nucleic Acids Res 2008; 36:D637-40.
47. Ewing RM, Chu P, Elisma F, et al. Large-scale mapping of human protein-protein interactions by mass spectrometry. Mol Syst Biol 2007;3:89.
48. Rual JF, Venkatesan K, Hao T, et al. Towards a proteomescale map of the human protein-protein interaction network. Nature 2005;437:1173-8.
49. Stelzl U, Worm U, Lalowski M, et al. A human proteinprotein interaction network: a resource for annotating the proteome. Cell 2005;122(6):957-68.
50. Xenarios I, Salwinski L, Duan XJ, et al. DIP, the database of interacting proteins: a research tool for studying cellular networks of protein interactions. Nucleic Acids Res 2002; 30(1):303-5.
51. Ashburner M, Ball CA, Blake JA, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000;25(1):25-9.
52. Jain E, Bairoch A, Duvaud S, et al. Infrastructure for the life sciences: design and implementation of the UniProt website. BMC Bioinformatics 2009;10:136.
53. Takigawa I, Tsuda K, Mamitsuka H. Mining significant substructure pairs for interpreting polypharmacology in drug-target network. PLoS One 2011;6(2):e16999.
54. Mitchell JB. The relationship between the sequence identities of alpha helical proteins in the PDB and the molecular similarities of their ligands. JChemInfComputSci 2001;41(6):1617-22.
55. Schuffenhauer A, Floersheim P, Acklin P, et al. Similarity metrics for ligands reflecting the similarity of the target proteins. J Chem Inf Comput Sci 2003;43(2):391-405.
56. Klabunde T. Chemogenomic approaches to drug discovery:similar receptors bind similar ligands. Br J Pharmacol 2007; 152(1):5-7.
57. Bleakley K, Biau G, Vert JP. Supervised reconstruction of biological networks with local models. Bioinformatics 2007; 23(13):i57-65.
58. Mordelet F, Vert JP. SIRENE: supervised inference of regulatory networks. Bioinformatics 2008;24(16):i76-82.
59. Vapnik VN. Statistical LearningTheory. New York: Wiley, 1998.
60. Cheng F, Liu C, Jiang J, et al. Prediction of drug-target interactions and drug repositioning via network-based inference. PLoSComput Biol 2012;8(5):e1002503.
61. Hattori M, Okuno Y, Goto S, et al. Development of a chemical structure comparison method for integrated analysis of chemical and genomic information in the metabolic pathways. JAmChemSoc 2003;125(39):11853-65.
62. Smith TF, Waterman MS. Identification of common molecular subsequences. JMol Biol 1981;147(1):195-7.
63. Davis J, Goadrich M. The relationship between Precision-Recall and ROC curves. ICML'06Proceedings of the 23rd international conference on machine learning Pittsburgh, USA, 2006. pp. 233-40. ACM, New York, 2006.
64. Chang CC, Lin CJ. LIBSVM: A library for support vector machines. ACM Trans Intell Syst Technol 2011;2(3):Article 27.
65. Kuhn M, Szklarczyk D, Franceschini A, et al. STITCH 3:zooming in on protein-chemical interactions. Nucleic Acids Res 2012;40:D876-80.
66. Keiser MJ, Setola V, Irwin JJ, et al. Predicting new molecular targets for known drugs. Nature 2009;462:175-81.
67. Garattini S. Are me-too drugs justified? J Nephrol 1997; 10(6):283-94.
68. Campillos M, Kuhn M, Gavin AC. Drug target identification using side-effect similarity. Science 2008;321:263-6.